The patent protects a novel crystalline form of zervimesine for treating Alzheimer's and dementia with Lewy bodies. The drug is currently in Phase 2 clinical trials.
The patent protects a novel crystalline form of zervimesine for treating Alzheimer's and dementia with Lewy bodies. The drug is currently in Phase 2 clinical trials.
@longevitytech.bsky.socialCognition Therapeutics will meet the agency on 20 October to agree on how a Phase 3 trial of zervimesine should measure success.
Link as first comment.
#longevity #geroscience #CognitionTherapeutics #Phase3 #zervimesine
